TNFRSF1B and neoplasm: To examine the in vivo effect of TNFR2-targeted nanoparticles on tumor growth, tumor-bearing mice were intravenously injected with PBS, free ADR, ISO-PLGA-ADR, or TNFR2-PLGA-ADR for 5 dosages every 3 d, starting on day 6 after tumor inoculation.